Skip to main content


Opinion statement

Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach. Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival. Surgical resection should proceed through a craniofacial approach if possible. The role of chemotherapy in the initial treatment paradigm is less clear. Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease. Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.

This is a preview of subscription content, access via your institution.

References and Recommended Reading

  1. 1.

    Broich G, Pagliari A, Ottaviani F: Esthesioneuroblastoma:a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997, 17:2683–2706. Excellent review with historical perspective.

    PubMed  CAS  Google Scholar 

  2. 2.

    Lund AR, Howard D, Wei W, et al.: Olfactory neuroblastoma:past, present, and future? Laryngoscope 2003, 113:502–507.

    PubMed  Article  Google Scholar 

  3. 3.

    Bradley PJ, Jones NS, Robertson I: Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg 2003, 11:112–118. This is a comprehensive review incorporating recent advances and providing specific treatment algorithms.

    PubMed  Article  Google Scholar 

  4. 4.

    Dulgerov P, Allal A, Calceterra T: Esthesioneuroblastoma:a meta-analysis and review. Lancet Oncol 2001, 2:683–690. A meta-analysis that highlights recent developments in diagnosis, staging, treatment, and outcomes in esthesioneuroblastoma.

    Article  Google Scholar 

  5. 5.

    Oskouian RJ, Jane JA, Dumont AS, et al.: Esthesioneuroblastoma:clinical presentation, radiological and pathological features, treatment, review of the literature, and the University of Virginia experience. Neurosurg Focus 2002, 12:1–9.

    Google Scholar 

  6. 6.

    Hyams VJ, Batsakis JG, Micheals L:Tumors of the upper respiratory tract and ear. In Atlas of Tumor Pathology. Edited by Hyams VJ, Batsakis JG, Michaels L. Washington, DC:Armed Forces Institute of Pathology; 1998:240–248.

    Google Scholar 

  7. 7.

    Kadish S, Goodman M, Wang CC: Olfactory neuroblastoma:a clinical analysis of 17 cases. Cancer 1976, 37:628–633.

    Google Scholar 

  8. 8.

    Morita A, Ebersold MJ, Olsen KD, et al.: Esthesioneuroblastoma:prognosis and management. Neurosurgery 1993, 32:706–715.

    PubMed  CAS  Article  Google Scholar 

  9. 9.

    Chamberlain MC: Treatment of intracranial metastatic esthesioneuroblastoma. Cancer 2002, 95:243–248.

    PubMed  Article  Google Scholar 

  10. 10.

    Dulguerov P, Calcaterra T: Esthesioneuroblastoma:the UCLA experience 1970–1990. Laryngoscope 1992, 102:843–849.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Eden BV, Debo RF, Larner JM, et al.: Esthesioneuroblastoma. Cancer 1994, 73:2556–2562.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Dias LD, Sa GM, Lima RA, et al.: Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003, 129:1186–1192.

    PubMed  Article  Google Scholar 

  13. 13.

    Gruber G, Laedrach K, Baumert B, et al.: Esthesioneuroblastoma:irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002, 54:486–491.

    PubMed  Article  Google Scholar 

  14. 14.

    Stieber VW, Munley M:Central nervous system tumors. In Intensity-Modulated Radiation Therapy (IMRT):A Clinical Perspective, edn 1. Edited by Mundt AJ, Roeske JC. Ontario, Canada:BC Decker Inc; 2005:231–263.

    Google Scholar 

  15. 15.

    Zabel A, Thilman C, Zuna I, et al.: Comparison of forward planned conformal radiation therapy and inverse planned intensity modulated radiation therapy for esthesioneuroblastoma. Br J Radiol 2002, 75:356–361.

    PubMed  CAS  Google Scholar 

  16. 16.

    Unger F, Haselsberger K, Walch C, et al.: Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wein) 2005, 147:595–602.

    Article  CAS  Google Scholar 

  17. 17.

    Sheehan JM, Sheehan JP, Jane JA, et al.: Chemotherapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000, 11:693–701.

    PubMed  CAS  Google Scholar 

  18. 18.

    Mishima Y, Nagasaki E, Terui Y, et al.: Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with esthesioneuroblastoma. Cancer 2004, 101:1437–1444.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Fitzek MM, Thornton AF, Varvares M, et al.: Neuroendocrine tumors of the sinonasal tract. Cancer 2002, 94:2623–2634.

    PubMed  Article  Google Scholar 

  20. 20.

    Eich HT, Hero B, Staar S, et al.: Multimodality therapy including radiotherapy and chemotherapy improves event free survival in stage C esthesioneuroblastoma. Strahlenther Onkol 2003, 179:233–240.

    PubMed  Article  Google Scholar 

  21. 21.

    Theilgaard SA, Buchwald C, Ingeholm P, et al.: Esthesioneuroblastoma:a Danish demographics study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003, 123:433–439.

    PubMed  Google Scholar 

  22. 22.

    Polin RS, Sheehan JP, Chenelle AG, et al.: The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma:the University of Virginia experience. Neurosurgery 1998, 42:1029–1037.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Diaz EM, Johnigan RH, Pero C, et al.: Olfactory neuroblastoma:the 22-year experience at one comprehensive cancer center. Head Neck 2005, 27:138–149.

    PubMed  Article  Google Scholar 

  24. 24.

    Resto JA, Eisele DW, Forastiere A, et al.: Esthesioneuroblastoma:the Johns Hopkins experience. Head and Neck 2000, 22:550–558.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Kim D, Jo Y, Kim J, et al.: Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 2004, 101:2257–2260.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Walch C, Stammberger H, Anderhuber W, et al.: The minimally invasive approach to olfactory neuroblastoma:combined endoscopic and stereotactic treatment. Laryngoscope 2000, 110:635–640.

    PubMed  Article  CAS  Google Scholar 

  27. 27.

    Devaiah AK, Larsen C, Tawfik, et al.: Esthesioneuroblastoma:endoscopic nasal and anterior craniotomy resection. Laryngoscope 2003, 113:2086–2090.

    PubMed  Article  Google Scholar 

  28. 28.

    Wick W, Wick A, Kuker W, et al.: Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. J Neurooncol 2004, 70:73–75.

    PubMed  Article  Google Scholar 

  29. 29.

    Constantinidis J, Steinhart H, Koch M, et al.: Olfactory neuroblastoma:the University of Erlangen-Nurenberg experience 1975–2000. Otolaryngol Head Neck Surg 2004, 130:567–574.

    PubMed  Article  Google Scholar 

Download references

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Klepin, H.D., McMullen, K.P. & Lesser, G.J. Esthesioneuroblastoma. Curr. Treat. Options in Oncol. 6, 509–518 (2005).

Download citation


  • Intensity Modulate Radiation Therapy
  • Main Drug Interaction
  • Blastoma
  • Hemorrhagic Cystitis
  • Cribriform Plate